Publications by authors named "T A Palaia"

Article Synopsis
  • - Nilotinib is an FDA-approved drug for chronic myeloid leukemia that may have potential neuroprotective effects, leading researchers to investigate its use in treating Alzheimer's disease (AD) and Parkinson's disease (PD).
  • - The study examined nilotinib's impact on amyloid processing and mitochondrial function in SH-SY5Y neuroblastoma cells, finding no significant changes in key gene expressions related to amyloid-β processing or neuronal health.
  • - While BACE1 and ADAM10 proteins were increased at certain nilotinib concentrations, overall results suggest that nilotinib does not effectively provide neuroprotection.
View Article and Find Full Text PDF

Purpose: Roux-en-Y gastric bypass (RYGB) leads to the improvement of many obesity-associated conditions. The degree to which post-operative macronutrient composition contributes to metabolic improvement after RYGB is understudied.

Methods: A mouse model of RYGB was used to examine the effects of diet on the post-operative outcomes of RYGB.

View Article and Find Full Text PDF

Mitochondrial degeneration in various neurodegenerative diseases, specifically in Alzheimer's disease, involves excessive mitochondrial fission and reduced fusion, leading to cell damage. P110 is a seven-amino acid peptide that restores mitochondrial dynamics by acting as an inhibitor of mitochondrial fission. However, the role of P110 as a neuroprotective agent in AD remains unclear.

View Article and Find Full Text PDF

Purpose: Bariatric surgery is emerging as an effective treatment for obesity and the metabolic syndrome. Recently, we demonstrated that Roux-en-Y gastric bypass (RYGB), but not vertical sleeve gastrectomy (VSG), resulted in improvements to white adipose physiology and enhanced brown adipose functioning. Since beneficial alterations to liver health are also expected after bariatric surgery, comparing the post-operative effects of RYGB and VSG on liver physiology is essential to their application in the treatment of non-alcoholic fatty liver disease (NAFLD).

View Article and Find Full Text PDF